Therapeutic effect of nimesulide on colorectal carcinogenesis in experimental murine ulcerative colitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 9, 2007, Pages 1474-1481

  Inoue, Takuya ^a   Murano, Mitsuyuki ^a,c   Abe, Yosuke ^a   Morita, Eijiro ^a   Murano, Naoko ^a   Yasumoto, Shingo ^a   Toshina, Ken ^a   Nishikawa, Takashi ^a   Maemura, Kentaro ^a   Hirata, Ichiro ^b   Katsu, Ken Ichi ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Department of Internal Medicine School of Medicine Fujita Health University ^*  (Japan)

Author keywords

Cancer; Cyclooxygenase 2; Dextran sulfate sodium; Dysplasia; Ulcerative colitis

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DEXTRAN SULFATE; NIMESULIDE; PROSTAGLANDIN E2;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CANCER INCIDENCE; CANCER PREVENTION; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DIET; DRUG EFFICACY; DYSPLASIA; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 34547993629     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04866.x     Document Type: Article

References (37)

1. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N. Eng J. Med. 1991 325 : 1593 6.
2. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res. 1993 53 : 1322 7.
3. Giovannucci E, Egan KM, Hunter DJ et al. Aspirin and the risk of colorectal cancer in women. N. Eng J. Med. 1995 333 : 609 14.
4. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993 14 : 1493 7.
5. Watson AJ. Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2. Histol. Histopathol. 1998 13 : 591 7.
6. Sakamoto C. Roles of COX-1 and COX-2 in gastrointestinal pathophysiology. J. Gastroenterol. 1998 33 : 618 24.
7. Kohno H, Suzuki R, Sugie S, Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 2005 5 : 46.
8. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 1990 323 : 1228 33.
9. Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 1996 39 : 87 92.
10. Suzuki S, Sakamoto S, Mitamura T, Sassa S, Kudo H, Yamashita Y. Preventive effects of sulphasalazine on colorectal carcinogenesis in mice with ulcerative colitis. In Vivo 2000 14 : 463 6.
11. Mitamura T, Sakamoto S, Sassa S, Suzuiki S, Kudo H, Okayasu I. The more an ulcerative colitis is repeated, the more the risk of colorectal carcinogenesis is increased in mice. Anticancer Res. 2002 22 : 3955 61.
12. Onose J, Imai T, Hasumura M, Ueda M, Hirose M. Rapid induction of colorectal tumors in rats initiated with 1,2-dimethylhydrazine followed by dextran sodium sulfate treatment. Cancer Lett. 2003 198 : 145 52.
13. Orii S, Yamaguchi T, Anzai H, Saito S, Chiba T, Suzuki K. Chemoprevention for colorectal tumorigenesis associated with chronic colitis in mice via apoptosis. J. Exp. Clin. Cancer Res. 2003 22 : 41 6.
14. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 2003 94 : 965 73.
15. Suzuki R, Kohno H, Sugie S, Tanaka T. Sequential observations on the occurrence of preneoplastic and neoplastic lesions in mouse colon treated with azoxymethane and dextran sodium sulfate. Cancer Sci. 2004 95 : 721 7.
16. Cooper HS, Murthy S, Kido K, Yoshitake H, Flanigan A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000 21 : 757 68.
17. Okayasu I, Yamada M, Mikami T, Yoshida T, Kanno J, Ohkusa T. Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J. Gastroenterol. Hepatol. 2002 17 : 1078 83.
18. Korenaga D, Takesue F, Kido K et al. Impaired antioxidant defense system of colonic tissue and cancer development in dextran sulfate sodium-induced colitis in mice. J. Surg. Res. 2002 102 : 144 9.
19. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig. Dis. Sci. 1993 38 : 1722 34.
20. Riddell RH, Goldman H, Ransohoff DF et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum. Pathol. 1983 14 : 931 68.
21. Brazowski E, Rozen P, Misonzhnick-Bedny F, Gitstein G. Characteristics of familial juvenile polyps expressing cyclooxygenase-2. Am. J. Gastroenterol. 2005 100 : 130 8.
22. Yamauchi T, Watanabe M, Kubota T et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis. Colon Rectum 2002 45 : 98 103.
23. Yang VW, Shields JM, Hamilton SR et al. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res. 1998 58 : 1750 3.
24. Hull MA, Booth JK, Tisbury A et al. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br. J. Cancer 1999 79 : 1399 405.
25. Bamba H, Ota S, Kato A, Adachi A, Itoyama S, Matsuzaki F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int. J. Cancer 1999 83 : 470 5.
26. Sonoshita M, Takaku K, Oshima M, Sugihara K, Taketo MM. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res. 2002 62 : 6846 9.
27. Sato T, Yoshinaga K, Okabe S et al. Cyclooxygenase-2 expression in colorectal adenomas. Dis. Colon Rectum 2003 46 : 786 92.
28. Einspahr JG, Krouse RS, Yochim JM et al. Association between cyclooxygenase expression and colorectal adenoma characteristics. Cancer Res. 2003 63 : 3891 3.
29. Shinozaki M, Watanabe T, Kubota Y et al. High proliferative activity is associated with dysplasia in ulcerative colitis. Dis. Colon Rectum 2000 43 : S34 9.
30. Sun Y, Tang XM, Half E et al. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 2002 62 : 6323 8.
31. Vetuschi A, Latella G, Sferra R et al. Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats. Dig. Dis. Sci. 2002 47 : 1447 57.
32. Miner PB Jr. Factors influencing the relapse of patients with inflammatory bowel disease. Am. J. Gastroenterol. 1997 92 : 1S 4S.
33. Forrest K, Symmons D, Foster P. Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? Aliment Pharmacol. Ther. 2004 20 : 1035 43.
34. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J. Clin. Invest. 1996 98 : 2076 85.
35. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000 119 : 706 14.
36. Tessner TG, Cohn SM, Schloemann S, Stenson WF. Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice. Gastroenterology 1998 115 : 874 82.
37. Hegazi RA, Mady HH, Melhem MF, Sepulveda AR, Mohi M, Kandil HM. Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice. Inflamm. Bowel Dis. 2003 9 : 230 6.